We have heard a lot of complaints around here.
Why can't we have a higher market cap than SAVA?
Why does Biogen get their drug approved while we get ignored?
Why does Annovis get all that attention?
Why can't we just take a shortcut and look at the 2b/3 data already?
Take a step back and look around you. Where is the recent competition?
SAVA is down 40 percent in two days, so far, on quite plausible allegations that they have falsified their trial data. If this proves out, not only is SAVA done as a company, but people may well go to jail.
Biogen has really suffered through a pyrrhic victory. Not only have their desperate shenanigans been called out during the Aduhelm approval process, but they are taking down the FDA's reputation down with them. Major players are refusing to consider offering or reimbursing payments for their drug which, as is generally agreed, is waaay overpriced, presents a high incidence of side effects, and basically just doesn't work. Biogen has little else going for it, and if they keep to their present course they are heading for a corporate disaster.
Annovis, a two person firm, has recently seen their stock drop from a high of $132 to today's $35.98 close. And for good reason -- they showed weak trial results at their last report.
And then, there's us. With Missling, the CEO that drives so many of you nuts because he takes so long and says so little. But he is playing an entirely different game than the competition. He is not playing to the gallery, true, but his team has undertaken a spectacularly ambitious drug development scheme that shows every sign of success. The analyses coming out of these slow motion trials are as sophisticated as anything you will find. And he has been upping the stakes, as well. Not only does he intend to produce a significantly disease modifying treatment for Alzheimer's -- which is more than the rest of the competitors put together -- but he is aiming at similar outcomes for a constantly widening range of CNS diseases: Parkinson's, Parkinson's Disease Dementia, Rett, Fragile X, and you can see more emerging on the horizon. It's stunning.
And Missling is not done raising the bar. He is now going to undertake an Alzheimer's prevention trial, maybe even a CNS-wide prevention trial. Watch what he is doing, not what other CEO's (I'm looking at you, SAVA) are saying. He is trying to build the next great pharma company if he can; he has built his corporate defenses against assault. The scientific engineering takes work and preparation and, though this great effort is right there in front of us, not everyone can see it. Or can wait for it. But the granite foundation is now being laid, and when this is done, it will be a sight to see. A doubling of the institutional ownership from last year is not an accident.
And even if the stock price is frustrating some people, it is way up. Way up. I hope you are loaded up already. But don't use that as the real interim look. Look at the science and the unbroken success of the science at Anavex by Missling and his team. That's the show.
AI
